Anti-STEAP1 CAR T-cells
PreclinicalCell therapy
Anti-STEAP1 CAR T-cells is one of 32 biologic programs targeting Prostate Cancer. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Viagra
VViatris Specialty LLC
Preclinical
Duragesic
CCephalon
Preclinical
Triptorelin Pamoate
IpsenPreclinical
Osmitrol
BB. Braun Medical Inc.
Preclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-STEAP1 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- FFred Hutchinson Cancer Center